167 related articles for article (PubMed ID: 25196678)
1. Tight blood glycaemic and blood pressure control in experimental diabetic nephropathy reduces extracellular matrix production without regression of fibrosis.
Conway BR; Betz B; Sheldrake TA; Manning JR; Dunbar DR; Dobyns A; Hughes J; Mullins JJ
Nephrology (Carlton); 2014 Dec; 19(12):802-13. PubMed ID: 25196678
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in experimental diabetic nephropathy.
Advani A; Wiggins KJ; Cox AJ; Zhang Y; Gilbert RE; Kelly DJ
Nephrology (Carlton); 2011 Aug; 16(6):573-81. PubMed ID: 21342330
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic and renoprotective effects of aliskiren in streptozotocin-induced diabetic nephropathy in female rats.
Mahfoz AM; El-Latif HA; Ahmed LA; Hassanein NM; Shoka AA
Naunyn Schmiedebergs Arch Pharmacol; 2016 Dec; 389(12):1315-1324. PubMed ID: 27612855
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective effects of berberine through regulation of the MMPs/TIMPs system in streptozocin-induced diabetic nephropathy in rats.
Ni WJ; Ding HH; Zhou H; Qiu YY; Tang LQ
Eur J Pharmacol; 2015 Oct; 764():448-456. PubMed ID: 26192633
[TBL] [Abstract][Full Text] [Related]
5. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy.
Mifsud S; Kelly DJ; Qi W; Zhang Y; Pollock CA; Wilkinson-Berka JL; Gilbert RE
Nephron Physiol; 2003; 95(4):p83-91. PubMed ID: 14694265
[TBL] [Abstract][Full Text] [Related]
6. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases.
McLennan SV; Kelly DJ; Cox AJ; Cao Z; Lyons JG; Yue DK; Gilbert RE
Diabetologia; 2002 Feb; 45(2):268-75. PubMed ID: 11935159
[TBL] [Abstract][Full Text] [Related]
7. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
8. Modeling Human Diabetic Kidney Disease by Combining Hyperglycemia and Hypertension in a Transgenic Rodent Model.
Cairns C; Conway B
Methods Mol Biol; 2020; 2067():41-52. PubMed ID: 31701444
[TBL] [Abstract][Full Text] [Related]
9. Hyperglycemia and renin-dependent hypertension synergize to model diabetic nephropathy.
Conway BR; Rennie J; Bailey MA; Dunbar DR; Manning JR; Bellamy CO; Hughes J; Mullins JJ
J Am Soc Nephrol; 2012 Mar; 23(3):405-11. PubMed ID: 22193383
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the development of renal injury in Type-1 diabetic Dahl salt-sensitive rats.
Slaughter TN; Paige A; Spires D; Kojima N; Kyle PB; Garrett MR; Roman RJ; Williams JM
Am J Physiol Regul Integr Comp Physiol; 2013 Oct; 305(7):R727-34. PubMed ID: 23926133
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension.
Kelly DJ; Zhang Y; Hepper C; Gow RM; Jaworski K; Kemp BE; Wilkinson-Berka JL; Gilbert RE
Diabetes; 2003 Feb; 52(2):512-8. PubMed ID: 12540629
[TBL] [Abstract][Full Text] [Related]
12. Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy.
Ma J; Wu H; Zhao CY; Panchapakesan U; Pollock C; Chadban SJ
Int J Clin Exp Pathol; 2014; 7(2):481-95. PubMed ID: 24551269
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin unmasks specific antioxidant pathways protective against albuminuria and kidney hypertrophy in a mouse model of diabetes.
Spencer NY; Yang Z; Sullivan JC; Klein T; Stanton RC
PLoS One; 2018; 13(7):e0200249. PubMed ID: 29979777
[TBL] [Abstract][Full Text] [Related]
14. The KCa3.1 blocker TRAM34 reverses renal damage in a mouse model of established diabetic nephropathy.
Huang C; Zhang L; Shi Y; Yi H; Zhao Y; Chen J; Pollock CA; Chen XM
PLoS One; 2018; 13(2):e0192800. PubMed ID: 29425253
[TBL] [Abstract][Full Text] [Related]
15. Salt restriction reduces hyperfiltration, renal enlargement, and albuminuria in experimental diabetes.
Allen TJ; Waldron MJ; Casley D; Jerums G; Cooper ME
Diabetes; 1997 Jan; 46(1):19-24. PubMed ID: 8971091
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
[TBL] [Abstract][Full Text] [Related]
17. Tropisetron ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats.
Barzegar-Fallah A; Alimoradi H; Asadi F; Dehpour AR; Asgari M; Shafiei M
Clin Exp Pharmacol Physiol; 2015 Apr; 42(4):361-8. PubMed ID: 25676798
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats.
Yamada S; Tanabe J; Ogura Y; Nagai Y; Sugaya T; Ohata K; Natsuki Y; Ichikawa D; Watanabe S; Inoue K; Hoshino S; Kimura K; Shibagaki Y; Kamijo-Ikemori A
Clin Exp Nephrol; 2021 Apr; 25(4):365-375. PubMed ID: 33409761
[TBL] [Abstract][Full Text] [Related]
19. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-27a targets Sfrp1 to induce renal fibrosis in diabetic nephropathy by activating Wnt/β-Catenin signalling.
Shi M; Tian P; Liu Z; Zhang F; Zhang Y; Qu L; Liu X; Wang Y; Zhou X; Xiao Y; Guo B
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32484208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
